Philip Bulterys

About Philip Bulterys

Philip was born in Los Angeles to a Belgian father and Chinese mother, both of whom were trained in epidemiology and public health. The family moved to Rwanda when Philip was one year old, where his parents conducted HIV research, but their work was disrupted by the Rwandan genocide. After a decade back in the U.S., the family moved to Zambia where Philip completed high school. He returned to Zambia following his freshman and sophomore years of college as a visiting researcher with the Malaria Institute at Macha.

Philip attended Stanford University where he majored in biology with a concentration in microbiology and immunology. At Stanford, Philip served as Director of Education for FACE AIDS, a national student organization, and volunteered as a middle school health tutor. He also conducted research on HIV/malaria coinfection and HIV evolution with Dr. Dmitri Petrov and Dr. David Katzenstein. He graduated with honors in 2010.

Philip entered the UCLA-Caltech Medical Scientist Training Program in 2010, received a Ph.D. in Molecular Biology in 2017, and his M.D. in 2019. For his Ph.D. thesis, Philip studied the Tier 1 select agent bacterial pathogens, Burkholderia pseudomallei and Burkholderia mallei, in the laboratory of Dr. Jeff F. Miller (member of the National Academy of Sciences). He developed a high-throughput small molecule screening platform that successfully identified several new therapeutic leads for these high-consequence pathogens, which he reported in a first-author article in PNAS in 2019. He also contributed to the discovery of novel features of Burkholderia pathogenesis. Philip’s M.D./Ph.D. training was supported by a Soros Fellowship for New Americans and an NIH NIAID F30 Fellowship.

Philip subsequently completed residency training in anatomic and clinical pathology (2019-2023), a chief residency in clinical pathology (2022-2023), and a hematopathology fellowship (2023-2024), all at Stanford Health Care. Philip is currently completing a fellowship in dermatopathology (2024-2025) at Stanford Health Care. During his residency and fellowship training, Philip has helped launch projects to optimize a low-cost transcriptional assay for lymphoma diagnosis in Sub-Saharan Africa, better define the histopathologic features of talaromycosis (a poorly-understood opportunistic fungal infection affecting HIV patients in South-East Asia), investigate the long-term impact of the COVID pandemic, and characterize the histologic and molecular features of rare hematolymphoid tumors. After his training, he intends to focus his efforts on improving the diagnosis and treatment of emerging and neglected infections, as well as cancers, in low-resource settings.